Reducing the Burden of Hypoglycemia: FLO23011 Improves Patient-Reported Outcomes and Identifies Glycemic Predictors of Treatment Success
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
To compare patient-reported outcomes (PROs) for hypoglycemia recovery with FLO23011, a glucose/beta-hydroxybutyrate Multi-Energy Substrate for Hypoglycemia (MESH) treatment, versus standard glucose gel in type 1 diabetes, contextualized by continuous glucose monitoring (CGM) analyses.
Research Design and Methods
In a randomized, open-label, crossover study, 12 adults with type 1 diabetes used FLO23011 or glucose gel to treat hypoglycemia during two 6-week CGM-monitored periods. PROs were assessed using 14-domain questionnaires and exit interviews. CGM analyses from a broader discovery analysis examined patient-relevant recovery signals: glucose-band exposure versus psychological PRO scores, and baseline glycemic variability versus time-in-range response.
Results
FLO23011 was rated more favorably than glucose gel in 13/14 domains, with 10 significant. Differences included speed of action (8.0 vs. 7.3; P = 0.025), after-effects reduction (8.0 vs. 6.2; P = 0.014), ease-of-use (8.9 vs. 4.9; P = 0.002), and overall management ability (8.5 vs. 7.4; P = 0.019). Interviews described faster cognitive recovery, reduced disruption, and greater confidence. Reduced Level 1 hypoglycemia exposure was associated with higher reduced-worry and management-ability ratings (ρ = 0.90; P = 0.037). Higher baseline coefficient of variation predicted greater time-in-range improvement with FLO23011 (ρ = 0.917; P = 0.0005).
Conclusions
FLO23011 showed more favorable patient-reported recovery than glucose gel. Initial CGM-PRO analyses findings suggest perceived benefit may align with reduced Level 1 hypoglycemia, while baseline variability may identify greater objective response. Results support integrating patient-reported and glycemic outcomes to evaluate hypoglycemia treatments, warranting confirmation in larger blinded studies.
